Discovery dashboard
What's new in drug repurposing this week
Live signals from 1,618 hypotheses tracked since 2026-05-12. 14 have reached strong support, 61 have partial support, 138 new PubMed citations recorded.
Last refresh: 2026-05-13
Hypotheses gaining literature support
New PubMed citations matching the drug × outcome pair since the 2026-05-12 snapshot. Strong support = 3+ new PMIDs or any phase-2+ trial; partial = 1-2 new PMIDs.
- #1 View trace →
- #2 View trace →
- #3 View trace →
- #4 View trace →
- #5 View trace →
Strong-support cohort
The full 14-hypothesis short list that crossed the strong-support threshold. What does this mean? A tracked hypothesis transitions to strong support when at least 3 new PubMed citations match the drug × outcome pair since the snapshot, or any phase-2+ clinical trial is registered. Partial = 1-2 new citations.
- resveratrol → PGC1α → inflammation +13 new PMIDs mid
- resveratrol → SIRT1 → inflammation +13 new PMIDs mid
- metformin → DR5 → apoptosis +6 new PMIDs mid
- pembrolizumab → PD-1 → prognosis +4 new PMIDs mid
- resveratrol → SIRT1 → proliferation +3 new PMIDs high
Drugs with the most active recruiting trials
Cross-referenced with the Robertium catalog: drugs that are actively recruiting patients and have novel cross-domain hypotheses are the highest-priority candidates for outreach.
- #1 View drug →
- #2 View drug →
- #3 View drug →
- #4 View drug →
- #5 View drug →
Featured case studies
Walk-throughs of why a specific hypothesis matters: source papers, mechanism, competitive landscape, limitations.